Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis

Obeticholic acid (OCA) is approved for the treatment of patients with primary biliary cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports of serious liver injury have raised concerns about its safety in cirrhosis. We investigated the effects of treatment with...

Full description

Bibliographic Details
Main Authors: Binu V. John, Kaley Schwartz, Cynthia Levy, Bassam Dahman, Yangyang Deng, Paul Martin, Tamar H. Taddei, David E. Kaplan
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1720
id doaj-e52c318199354e8384535aedfb7cbf35
record_format Article
spelling doaj-e52c318199354e8384535aedfb7cbf352021-08-17T12:59:15ZengWileyHepatology Communications2471-254X2021-08-01581426143610.1002/hep4.1720Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and CirrhosisBinu V. John0Kaley Schwartz1Cynthia Levy2Bassam Dahman3Yangyang Deng4Paul Martin5Tamar H. Taddei6David E. Kaplan7Division of Hepatology Bruce W Carter VA Medical Center Miami FL USADivision of Hepatology Bruce W Carter VA Medical Center Miami FL USADivision of Digestive Health and Liver Diseases University of Miami Miller School of Medicine Miami FL USADepartment of Health Behavior and Policy Virginia Commonwealth University Richmond VA USADepartment of Health Behavior and Policy Virginia Commonwealth University Richmond VA USADivision of Digestive Health and Liver Diseases University of Miami Miller School of Medicine Miami FL USASection of Digestive Diseases Yale School of Medicine New Haven CT USADivision of Gastroenterology and Hepatology University of Pennsylvania Philadelphia PA USAObeticholic acid (OCA) is approved for the treatment of patients with primary biliary cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports of serious liver injury have raised concerns about its safety in cirrhosis. We investigated the effects of treatment with OCA on hepatic decompensation and liver‐related mortality or transplantation in a cohort with compensated PBC cirrhosis. This was a retrospective cohort study using national data of US veterans with PBC and cirrhosis. We performed a propensity score model using variables associated with OCA prescription to control for baseline risk of decompensation. New OCA users were matched to nonusers. We identified 509 subjects with compensated PBC cirrhosis. We developed a propensity score model using variables associated with OCA prescription; 21 OCA users were matched with 84 nonusers. Over 569 and 3,847 person‐months, respectively, of follow‐up, 5 (23.8%) OCA users and 22 (26.2%) OCA nonusers decompensated. The C‐statistic of the propensity score model was 0.87. On multivariable analysis, after adjusting for potential confounders, OCA use was associated with an increased risk of hepatic decompensation (adjusted hazard ratio, 3.9; 95% confidence interval, 1.33‐11.57; P = 0.01). There was no association between OCA use and liver‐related mortality or transplantation (adjusted hazard ratio, 1.35; 95% confidence interval, 0.35‐5.21; P = 0.66). Conclusion: OCA use was associated with an increase in hepatic decompensation but not liver‐related mortality or transplantation in patients with compensated PBC cirrhosis. Additional studies are recommended to prospectively investigate these findings.https://doi.org/10.1002/hep4.1720
collection DOAJ
language English
format Article
sources DOAJ
author Binu V. John
Kaley Schwartz
Cynthia Levy
Bassam Dahman
Yangyang Deng
Paul Martin
Tamar H. Taddei
David E. Kaplan
spellingShingle Binu V. John
Kaley Schwartz
Cynthia Levy
Bassam Dahman
Yangyang Deng
Paul Martin
Tamar H. Taddei
David E. Kaplan
Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
Hepatology Communications
author_facet Binu V. John
Kaley Schwartz
Cynthia Levy
Bassam Dahman
Yangyang Deng
Paul Martin
Tamar H. Taddei
David E. Kaplan
author_sort Binu V. John
title Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
title_short Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
title_full Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
title_fullStr Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
title_full_unstemmed Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
title_sort impact of obeticholic acid exposure on decompensation and mortality in primary biliary cholangitis and cirrhosis
publisher Wiley
series Hepatology Communications
issn 2471-254X
publishDate 2021-08-01
description Obeticholic acid (OCA) is approved for the treatment of patients with primary biliary cholangitis (PBC) who are partial responders or intolerant to ursodeoxycholic acid. Reports of serious liver injury have raised concerns about its safety in cirrhosis. We investigated the effects of treatment with OCA on hepatic decompensation and liver‐related mortality or transplantation in a cohort with compensated PBC cirrhosis. This was a retrospective cohort study using national data of US veterans with PBC and cirrhosis. We performed a propensity score model using variables associated with OCA prescription to control for baseline risk of decompensation. New OCA users were matched to nonusers. We identified 509 subjects with compensated PBC cirrhosis. We developed a propensity score model using variables associated with OCA prescription; 21 OCA users were matched with 84 nonusers. Over 569 and 3,847 person‐months, respectively, of follow‐up, 5 (23.8%) OCA users and 22 (26.2%) OCA nonusers decompensated. The C‐statistic of the propensity score model was 0.87. On multivariable analysis, after adjusting for potential confounders, OCA use was associated with an increased risk of hepatic decompensation (adjusted hazard ratio, 3.9; 95% confidence interval, 1.33‐11.57; P = 0.01). There was no association between OCA use and liver‐related mortality or transplantation (adjusted hazard ratio, 1.35; 95% confidence interval, 0.35‐5.21; P = 0.66). Conclusion: OCA use was associated with an increase in hepatic decompensation but not liver‐related mortality or transplantation in patients with compensated PBC cirrhosis. Additional studies are recommended to prospectively investigate these findings.
url https://doi.org/10.1002/hep4.1720
work_keys_str_mv AT binuvjohn impactofobeticholicacidexposureondecompensationandmortalityinprimarybiliarycholangitisandcirrhosis
AT kaleyschwartz impactofobeticholicacidexposureondecompensationandmortalityinprimarybiliarycholangitisandcirrhosis
AT cynthialevy impactofobeticholicacidexposureondecompensationandmortalityinprimarybiliarycholangitisandcirrhosis
AT bassamdahman impactofobeticholicacidexposureondecompensationandmortalityinprimarybiliarycholangitisandcirrhosis
AT yangyangdeng impactofobeticholicacidexposureondecompensationandmortalityinprimarybiliarycholangitisandcirrhosis
AT paulmartin impactofobeticholicacidexposureondecompensationandmortalityinprimarybiliarycholangitisandcirrhosis
AT tamarhtaddei impactofobeticholicacidexposureondecompensationandmortalityinprimarybiliarycholangitisandcirrhosis
AT davidekaplan impactofobeticholicacidexposureondecompensationandmortalityinprimarybiliarycholangitisandcirrhosis
_version_ 1721205147421376512